UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models

Anticancer research, 2017-02, Vol.37 (2), p.623-630

2017

Volltextzugriff (PDF)

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Chemical and Pharmaceutical Bulletin, 2008/11/01, Vol.56(11), pp.1555-1561

2008

Volltextzugriff (PDF)

Dichroic rugate filters based on birefringent porous silicon

Optics express, 2008-09, Vol.16 (20), p.15531-15539

2008

Volltextzugriff (PDF)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

Oncology reports, 2022-02, Vol.47 (2)

2022

Volltextzugriff (PDF)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

International journal of oncology, 2017-08, Vol.51 (2), p.425-434

2017

Volltextzugriff (PDF)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L[1.sup.low] and immune desert-like mouse tumors

Oncology reports, 2022-02, Vol.47 (2), p.1

2022

Volltextzugriff (PDF)

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Oncology reports, 2021-12, Vol.47 (2), Article 36

2021

Volltextzugriff (PDF)

Abstract B046: Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B046-B046

2019

Volltextzugriff (PDF)

Vitamin D Hormone Inhibits Osteoclastogenesis In Vivo by Decreasing the Pool of Osteoclast Precursors in Bone Marrow

Journal of bone and mineral research, 2002-04, Vol.17 (4), p.622-629

2002

Volltextzugriff (PDF)

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Oncology reports, 2022-02, Vol.47 (2)

2022

Volltextzugriff (PDF)

Discovery and structure–activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists

Bioorganic & medicinal chemistry letters, 2007-10, Vol.17 (20), p.5573-5576

2007

Volltextzugriff (PDF)

Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity

The Prostate, 2010-05, Vol.70 (7), p.745-754

2010

Volltextzugriff (PDF)

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab

Journal of gastroenterology, 2015-04, Vol.50 (4), p.467-479

2015

Volltextzugriff (PDF)

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Chemical and Pharmaceutical Bulletin, 2009/10/01, Vol.57(10), pp.1178-1178

2009

Volltextzugriff (PDF)

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells

International journal of oncology, 2015-04, Vol.46 (4), p.1560-1572

2015

Volltextzugriff (PDF)

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10

The Prostate, 2010-04, Vol.70 (5), p.457-466

2010

Volltextzugriff (PDF)

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291

The Prostate, 2011-09, Vol.71 (12), p.1344-1356

2011

Volltextzugriff (PDF)

Porous silicon based extended-bandwidth rugate filters for mid-infrared application

Infrared physics & technology, 2010-07, Vol.53 (4), p.292-294

2010

Volltextzugriff (PDF)

Broadband rugate filters based on porous silicon

Optical materials, 2008-09, Vol.31 (1), p.102-105

2008

Volltextzugriff (PDF)

Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

Bioorganic & medicinal chemistry, 2010-12, Vol.18 (23), p.8150-8157

2010

Volltextzugriff (PDF)

Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

Bioorganic & medicinal chemistry, 2010-05, Vol.18 (9), p.3159-3168

2010

Volltextzugriff (PDF)

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

The Prostate, 2011, Vol.71 (12), p.1344-1356

2011

Volltextzugriff (PDF)

Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships

Bioorganic & medicinal chemistry, 2007, Vol.15 (1), p.174-185

2007

Volltextzugriff (PDF)

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A220-A220

2009

Volltextzugriff (PDF)

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A219-A219

2009

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Aktive Filter

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(69)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Dichroic rugate filters based on birefringent porous silicon

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L[1.sup.low] and immune desert-like mouse tumors

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Abstract B046: Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model

Vitamin D Hormone Inhibits Osteoclastogenesis In Vivo by Decreasing the Pool of Osteoclast Precursors in Bone Marrow

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Discovery and structure–activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists

Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291

Porous silicon based extended-bandwidth rugate filters for mid-infrared application

Broadband rugate filters based on porous silicon

Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Aktive Filter

Suchergebnisse filtern